FDA Maps Out Potential 510(k) Reforms In Long-Awaited Report
This article was originally published in The Pink Sheet Daily
At first blush, industry organizations agree changes could be viewed as positives for device makers, but the ultimate impact of the proposals will depend on how they are implemented.
You may also be interested in...
The Institute of Medicine committee charged with recommending reforms to FDA's 510(k) clearance program will move the remainder of its efforts behind closed doors
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.